JP7000458B2 - 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療 - Google Patents

長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療 Download PDF

Info

Publication number
JP7000458B2
JP7000458B2 JP2019563100A JP2019563100A JP7000458B2 JP 7000458 B2 JP7000458 B2 JP 7000458B2 JP 2019563100 A JP2019563100 A JP 2019563100A JP 2019563100 A JP2019563100 A JP 2019563100A JP 7000458 B2 JP7000458 B2 JP 7000458B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hadsc
composition according
administration
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019563100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519658A (ja
Inventor
マロム，エフド
キメルマン，ナダブ ブレイク
グリンスパン，フリーダ
Original Assignee
ステム セル メディスン リミテッド
マピ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステム セル メディスン リミテッド, マピ ファーマ リミテッド filed Critical ステム セル メディスン リミテッド
Publication of JP2020519658A publication Critical patent/JP2020519658A/ja
Application granted granted Critical
Publication of JP7000458B2 publication Critical patent/JP7000458B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019563100A 2017-05-15 2017-05-15 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療 Expired - Fee Related JP7000458B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2017/050535 WO2018211486A1 (en) 2017-05-15 2017-05-15 Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells

Publications (2)

Publication Number Publication Date
JP2020519658A JP2020519658A (ja) 2020-07-02
JP7000458B2 true JP7000458B2 (ja) 2022-02-10

Family

ID=64273438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563100A Expired - Fee Related JP7000458B2 (ja) 2017-05-15 2017-05-15 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療

Country Status (8)

Country Link
US (1) US11413311B2 (enExample)
EP (1) EP3624815A4 (enExample)
JP (1) JP7000458B2 (enExample)
CN (1) CN110709091A (enExample)
AU (1) AU2017414803B2 (enExample)
CA (1) CA3062964C (enExample)
IL (1) IL270355B2 (enExample)
WO (1) WO2018211486A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
AU2018242998B2 (en) * 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521796A (ja) 2004-11-29 2008-06-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療
JP2013516403A (ja) 2010-01-04 2013-05-13 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
US20170065638A1 (en) 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
JP2020519645A (ja) 2017-05-15 2020-07-02 ステム セル メディスン リミテッド 脂肪組織由来幹細胞による多発性硬化症の治療

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
DK1248643T3 (da) 2000-01-20 2005-11-07 Yeda Res & Dev Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
NZ569331A (en) 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
WO2006060779A2 (en) 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
CA2668200C (en) 2006-11-03 2017-04-18 Multiple Sclerosis Research Center Of New York Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
WO2011041240A1 (en) 2009-09-30 2011-04-07 The Brigham And Women's Hospital, Inc. Tissue transplant compositions and methods for use
US8703180B1 (en) 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
EP2278873B1 (en) 2008-03-19 2015-05-06 Cryo-Save AG Improved cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US20090291061A1 (en) 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
DK2285951T3 (en) 2008-05-28 2018-10-22 Univ Ramot TREATMENT OF CNS DISEASES OF CNS DISEASES
WO2010014990A2 (en) 2008-08-01 2010-02-04 The Board Of Trustees Of The University Of Illinois Method of promoting neurogenesis by modulating secretase activities
WO2010028051A2 (en) 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
WO2010045645A1 (en) 2008-10-17 2010-04-22 Baxter International Inc. Methods of obtaining cell populations from adipose tissue
JP5515319B2 (ja) 2009-02-23 2014-06-11 富士レビオ株式会社 脂肪細胞への分化誘導培地及び方法
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
KR101788885B1 (ko) 2009-07-09 2017-10-20 타이제닉스, 에스.에이.유. 세포 요법에 사용하기 위한 방법 및 조성물
US8377885B2 (en) * 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US20110212158A1 (en) 2010-02-18 2011-09-01 Samson Tom Immunocompatible chorionic membrane products
AU2011343736A1 (en) * 2010-12-17 2013-05-02 Anthrogenesis Corporation Treatment of immune-related diseases and disorders using amnion derived adherent cells
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US20130034524A1 (en) 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
SG10201606745XA (en) 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
CL2011002642A1 (es) 2011-10-24 2012-04-09 Univ Del Desarrollo Uso de una composicion formada por un glucocorticoide y una tiazolinediona que sirve para inducir la diferenciacion adipogenica en celulas madres.
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
SG10201607521PA (en) 2012-03-12 2016-10-28 Univ Singapore Generation of brown adipose tissue (bat) from mesenchymal cells
TWI642781B (zh) 2014-02-06 2018-12-01 仲恩生醫科技股份有限公司 具優異細胞保護及免疫調節之ｑｕａｄｒｉ－正之基質細胞
AU2017218143B2 (en) 2016-02-12 2023-08-03 Cell Care Therapeutics, Inc. Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
US12161688B2 (en) * 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521796A (ja) 2004-11-29 2008-06-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療
JP2013516403A (ja) 2010-01-04 2013-05-13 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
US20170065638A1 (en) 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
JP2020519645A (ja) 2017-05-15 2020-07-02 ステム セル メディスン リミテッド 脂肪組織由来幹細胞による多発性硬化症の治療

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｊｏｕｒｎａｌ ｏｆ Ｔｒａｎｓｌａｔｉｏｎａｌ Ｍｅｄｉｃｉｎｅ，ＢｉｏＭｅｄ Ｃｅｎｔｒａｌ，2009年04月24日，７，29
Ｍｅｄｉａｔｏｒｓ ｏｆ Ｉｎｆｌａｍｍａｔｉｏｎ，Ｈｉｎｄａｗｉ Ｐｕｂｌｉｓｈｉｎｇ，2016年09月28日
Ｎａｔｕｒｅ Ｒｅｖｉｅｗｓ Ｎｅｕｒｏｌｏｇｙ，Ｓｐｒｉｎｇｅｒ Ｎａｔｕｒｅ，2010年04月20日，６，５，247-255

Also Published As

Publication number Publication date
EP3624815A1 (en) 2020-03-25
US20200147141A1 (en) 2020-05-14
US11413311B2 (en) 2022-08-16
IL270355A (enExample) 2019-12-31
IL270355B2 (en) 2023-06-01
CA3062964C (en) 2024-11-12
CN110709091A (zh) 2020-01-17
AU2017414803A1 (en) 2019-12-05
IL270355B1 (enExample) 2023-02-01
JP2020519658A (ja) 2020-07-02
WO2018211486A1 (en) 2018-11-22
CA3062964A1 (en) 2018-11-22
AU2017414803B2 (en) 2025-02-13
EP3624815A4 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
JP6725413B2 (ja) 炎症の治療のための免疫修飾粒子
EP3478300B1 (en) Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
JP5916622B2 (ja) グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
KR102139267B1 (ko) 펩티드 접합된 입자
JP5909745B2 (ja) 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬
US20190083495A1 (en) Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
JP7602322B2 (ja) 進行型の多発性硬化症を治療するためのグラチラマーデポシステム
KR20120100962A (ko) 신장 손상을 치료하는데 사용하기 위한 조혈 줄기 세포
JP7000458B2 (ja) 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
JP2020519645A (ja) 脂肪組織由来幹細胞による多発性硬化症の治療
US12178849B2 (en) Autoimmune disease treatment with chemokine-loaded alginate microparticles
JP6573293B2 (ja) 炎症性疾患の予防または治療用ペプチド及びこの用途
JP2019516803A (ja) 医薬組成物及び自己免疫疾患の治療におけるその使用
KR102383866B1 (ko) 자가 면역 질병 및 당뇨병의 치료를 위한 바이러스 벡터 및 그의 제조방법 및 응용
US20230218572A1 (en) Compositions and methods for improved mesenchymal stem cell therapy
JP2020527573A (ja) 強皮症関連血管障害を治療または改善するための組成物および方法
US20160022772A1 (en) Cytokine Receptors as Targets for Hypertension Therapy and Methods of Use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211223

R150 Certificate of patent or registration of utility model

Ref document number: 7000458

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees